Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0AVJCO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AOC-1020
|
|||||
| Synonyms |
AOC 1020; AOC-1020; AOC-FSHD; AOC1020
Click to Show/Hide
|
|||||
| Organization |
Avidity Biosciences, Inc.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
Undisclosed
|
|||||
| Antibody Name |
Delpacibart
|
Antibody Info | ||||
| Antigen Name |
Transferrin receptor protein 1 (TFRC)
|
Antigen Info | ||||
| Payload Name |
DUX4 siRNA
|
Payload Info | ||||
| Therapeutic Target |
Double homeobox protein 4 (DUX4)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
braxlosiran
|
|||||
| Special Approval(s) |
Fast track(FDA); Orphan drug(FDA)
|
|||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05747924 | Clinical Status | Phase 1 | ||
| Clinical Description | A randomized, double-blind, placebo-controlled, phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of AOC 1020 administered intravenously to adult participants with facioscapulohumeral muscular dystrophy (FSHD). | ||||
References